Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › onabotulinumtoxinA

onabotulinumtoxinA

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of onabotulinumtoxinA

31 trials tracked of onabotulinumtoxinA: 24 in phase 3 or 4 and 7 with published results. The most-cited published study has 197 citations.

31Trials tracked
24Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 13 Phase 3 11 Phase 2 6 Other / NA 1
  1. Phase 4 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine Completed · 197 cited
  2. Phase 4 Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults Completed · 103 cited
  3. Phase 4 The Treatment of Glabellar Frown Lines Completed · 48 cited
  4. Phase 3 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed · 27 cited
  5. Phase 4 Functional Effects of Botox on the Brain Using MRS and fMRI Completed · 24 cited
  6. Phase 4 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder Completed · 19 cited
Show 25 more trials
  1. Phase 4 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence Completed · 1 cited
  2. Phase 4 Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) Completed
  3. Phase 4 Calcitonin Gene-related Peptide Levels in Chronic Migraine Completed
  4. Phase 4 Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds Completed
  5. Phase 4 Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Completed
  6. Phase 4 Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®) Completed
  7. Phase 4 A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides Completed
  8. Phase 4 A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency Completed
  9. Phase 3 A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides Completed
  10. Phase 3 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides Completed
  11. Phase 3 Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients Completed
  12. Phase 3 A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity Completed
  13. Phase 3 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence Completed
  14. Phase 3 A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence Completed
  15. Phase 3 A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence Completed
  16. Phase 3 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed
  17. Phase 3 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed
  18. Phase 3 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines Completed
  19. Phase 2 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence Completed
  20. Phase 2 Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study Completed
  21. Phase 2 Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population Completed
  22. Phase 2 Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines Completed
  23. Phase 2 OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females Completed
  24. Phase 2 BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis Completed
  25. N/A A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
OnabotulinumtoxinA remains the most established procedural intervention for chronic migraine prevention
Neurology Meta-analysis
OnabotulinumtoxinA remains the most established procedural intervention for chronic migraine prevention OnabotulinumtoxinA Shows Most Established Evidence for Chronic Migraine Prevention
This umbrella review synthesizes evidence for various procedural interventions in chronic migraine, identifying onabotulinumtoxinA as the mo…
OnabotulinumtoxinA has the clearest evidence for chronic migraine prevention, while other procedures like nerve blocks and acupuncture show …
Frontiers Oct 12, 2026
OnabotulinumtoxinA 72 U reduces masseter prominence versus placebo in adults
Drug Pipeline RCT
OnabotulinumtoxinA 72 U reduces masseter prominence versus placebo in adults Does this shot really shrink a prominent jaw muscle, or is it just a placebo effect?
This Phase 3, randomized, placebo-controlled trial in 376 adults with Grade 4 or 5 masseter muscle prominence found that onabotulinumtoxinA …
An injection shrinks prominent jaw muscles in over half of adults with severe cases, narrowing the lower face quickly with mostly mild side …
Apr 18, 2026
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA
Drug Pipeline Phase III
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA Adding atogepant to botulinum toxin reduced migraine days in a small study
This Phase 3, multicenter, 24-week, open-label, single arm study evaluated add-on atogepant 60 mg once daily in 75 participants with chronic…
Adding atogepant to botulinum toxin cut migraine days by over 50% for 62% of patients in a study, with most finding it safe and well-tolerat…
Apr 18, 2026